Register

Registration

Note : After Answered of Questionnaires / Survey Please Close it.
.

Solara Active Pharma Sciences Ltd . Mid Cap

BSE: 541540 | NSE: SOLARA
Pharmaceuticals
Live
20/04/2021 4:00:00 PM
1460.40 -1.30   (-0.09%)
BSE: price shown with 5 mins delayed.
Prev. Close 1461.70
Open Price 1480.00
Volume Traded 9186.00

Fundamentals

Year on Year Growth Rate (%)

Ajusted EPS Sales Adjusted Net Profit

Latest Financials

Standalone Consolidated
TTM EPS (Rs) 50.65 50.81
TTM Sales (Rs. Cr.) 1469.44 1469.44
BVPS (Rs.) 411.57 410.50
Reserves (Rs. Cr.) 1442.82 1439
P/BV 3.53 3.54
PE 28.67 28.58197
From the Market
52 Week High / Low (Rs) 1625/439
All Time High / Low (Rs) 288/133.5
Volume Traded 9186
Market Cap (Rs. Cr.) 5217.9
Equity (Rs. Cr.) 35.929767
Face Value (Rs) 10
Industry PE 0

Quarterly Results

Quarterly Growth Rate (%)

Ajusted EPS Sales Net Profit Margin

Peers Data

Name Current Price(Rs) Market Cap. (Rs. cr.) Net Profit(Rs. cr.) Sales Growth(%)
Ambalal Sarabhai Enterprises Ltd 21.55 165.14 0 0.00
Fermenta Biotech Ltd 305.9 900.29 63.67 25.48
Bliss GVS Pharma Ltd 97.1 1001.55 92.33 -18.48
Unichem Laboratories Ltd 329 2316.35 -56.32 -4.64
Alembic Ltd 104.8 2691.07 93.55 -40.59
Solara Active Pharma Sciences Ltd 1452.25 5217.9 112.49 -11.28
Aurobindo Pharma Ltd 987.4 57855.58 1872.74 -11.37
Cipla Ltd 949.3 76557.56 2318.17 -39.44
Dr Reddys Laboratories Ltd 5153.95 85710.93 2937.7 -15.73
Divis Laboratories Ltd 3783.8 100448 1372.71 -4.34
Sun Pharmaceuticals Industries Ltd 645.05 154769.1 3211.14 -20.62

Technical

Sector

23387.09 280.75   (1.22%)

Index

47705.80 -243.62   (-0.51%)
9 Days Avg
Span A Span B 52 Week TenKan-Sen Kijun-Sen ChiKou-Sen
9 Days Avg

Score

Kindly subscribe to get access

Research Analytical

Kindly subscribe to get access

News

2021/04/10 11:14

Board of Solara Active Pharma Sciences approves scheme of amalgamation At meeting held on 09 April 2021

The Board of Directors of Solara Active Pharma Sciences on 09 April 2021 has approved the amalgamation of Aurore, Empyrean and Hydra with Solara.

The combination creates a pure play API company of scale with strong presence in Regulated Markets, Emerging Markets, a broad product portfolio, robust operations infrastructure, excellent R&D capabilities and clear synergies to further accelerate growth for the combined entity.

The merger is EPS accretive to Solara and will enhance other important financial ratios for Solara. The merger is in line with Solara's strategy of accelerating growth via appropriate inorganic actions. The combined entity will have the scale of market presence and product portfolio combined with robust manufacturing and R&D infrastructure to grow into a leading global pure play API and CRAMS company.

Shareholders of Aurore Life Sciences and Hydra Active Pharma Sciences shall be issued 1,32,94,800 equity shares of Solara Active Pharma Sciences. Pursuant to which, the shareholders of the Transferor Companies would have 27% stake in Solara Active Pharma Sciences.

With this merger, Aurore Life Science, Empyrean Lifesciences Private and Hydra Active Pharma Sciences shall be merged into Solara Active Pharma Sciences and post-merger, Solara will hold 67% stake in Aurore Pharmaceuticals.

Post-Merger, Promoter group holding shall be 44.18% and Public holding shall be 55.82%.

The Appointed Date for the merger would be 1 April, 2021 and the merger process is expected to be completed in Q4 FY 2021-22.

The merger is subject to certain conditions including approvals from stock exchanges, SEBI, shareholders, creditors, jurisdictional National Company Law Tribunal and other applicable statutory authorities.

Powered by Capital Market - Live News

2021/03/31 12:30

Board of Solara Active Pharma Sciences approves allotment of 20,000 shares under ESOP At meeting held on 31 March 2021

The Board of Solara Active Pharma Sciences at its meeting held on 31 March 2021 has approved the allotment of 20,000 equity shares against the Solara Employee Stock Option Plan 2018. Consequent to the said allotment, the paid-up share capital of the Company will increase from Rs. 35,90,97,670 consisting of 3,59,09,767 equity shares of Rs. 10 each to Rs. 35,92,97,670 consisting of 3,59,29,767 equity shares of Rs. 10 each.

The also approved the grant of 20,000 stock options under Solara Employee Stock Option Plan, 2018.

Powered by Capital Market - Live News

2021/03/31 12:21

Board of Solara Active Pharma Sciences approves retirement of ED- Finance At meeting held on 31 March 2021

The Board of Solara Active Pharma Sciences at its meeting held on 31 March 2021 has approved the retirement of S. Hariharan (DIN 05297969) from the position of Executive Director - Finance with effect from 31 March 2021, as per Company's succession plan.

S. Hariharan, will be succeeded by Subhash Anand, who was appointed as Executive Director and Chief Financial Officer of the Company with effect from 01 April 2021.

Powered by Capital Market - Live News

About Company